Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02160106 · ClinicalTrials.gov registry record · Phase 1
First in Human Dose Escalation Study of Vactosertib (TEW-7197) in Subjects With Advanced Stage Solid Tumors
A Phase 1 study, sponsored by MedPacto.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
NCT02160106 is a Phase 1 study that has completed, run by MedPacto. The registered enrollment target is 35 participants.
The verdict
NCT02160106, a Phase 1 study, has completed, sponsored by MedPacto.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
The phase I dose escalation study will investigate the safety, tolerability, and pharmacokinetics of the TGF-β pathway inhibitor TEW 7197 in subjects with advanced, refractory solid tumors.
Interventions
- DRUG TEW-7197
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2014-07-29 |
| Est. Completion | 2018-08-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02160106
The ClinicalTrials.gov registry entry for NCT02160106 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedPacto, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TEW-7197 is the first listed.
NCT02160106 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02160106 about?
NCT02160106 is a clinical study titled "First in Human Dose Escalation Study of Vactosertib (TEW-7197) in Subjects With Advanced Stage Solid Tumors". The phase I dose escalation study will investigate the safety, tolerability, and pharmacokinetics of the TGF-β pathway inhibitor TEW 7197 in subjects with advanced, refractory solid tumors.
What is the current status of trial NCT02160106?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2014-07-29. Estimated completion is 2018-08-28.
What interventions are being tested in trial NCT02160106?
The interventions under investigation include: TEW-7197 (DRUG).
Who is sponsoring clinical trial NCT02160106?
This trial is sponsored by MedPacto, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.